Caris Life Sciences Stock

carislifesciences.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $465MM

Operator of a biotechnology company specializing in cancer treatment agents. The company is a provider of molecular science focused on fulfilling the promise of precision medicine and facilitating a deeper understanding of cancer biology and other complex diseases through a suite of molecular profiling offerings assess DNA, RNA and proteins that reveal the molecular blueprint, enabling physicians and cancer patients to make more precise and personalized treatment decisions.

Register To Buy and Sell Shares

For more details on financing and valuation for Caris Life Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Caris Life Sciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Caris Life Sciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

David Halbert
Co-Founder, Chairman and Chief Executive Officer
Ginger Appleberry JD
Chief Compliance Officer & Associate General Counsel
Brian Lamon Ph.D
Chief Business Officer & Head of BioPharma Business Development
Thomas Parker
Chief Financial Officer and Senior Vice President
Ronald Merlino
Senior Vice President & Chief Information Officer
Jim Abraham
Chief Data Officer & Senior Vice President
David Spetzler Ph.D
President & Chief Scientific Officer
Stephanie Thomas
Chief of Staff, Executive Vice President & Office of the CEO

Board Members

Peter Castleman
J.H. Whitney Capital Partners
Vijay Mohan
Sixth Street Specialty Lending

Frequently Asked Questions About Caris Life Sciences’ Stock

Can you buy Caris Life Sciences’ stock?
Caris Life Sciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Caris Life Sciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Caris Life Sciences’ stock?
Yes, you can sell stock of a private company like Caris Life Sciences. Forge can help you sell your Caris Life Sciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Caris Life Sciences’ stock price?
Caris Life Sciences is a privately held company and therefore does not have a public stock price. However, you may access Caris Life Sciences’ private market stock price with Forge Data.
What is Caris Life Sciences’ stock ticker symbol?
Caris Life Sciences does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Caris' Precision Oncology Alliance Welcomes the OU Health Stephenson Cancer Center
OU Health Stephenson Cancer Center joins Caris' extensive network of leading cancer institutions committed to utilizing clinical data to advance patient care and outcomes
In Brief This Week: Illumina, Caris Life Sciences, Fresenius Medical Care, More
News items for the week of April 11, 2022.
In Brief This Week: Ginkgo Bioworks, Caris Life Sciences, MDxHealth, and More
News items for the week of Oct. 25, 2021.
Updated on: Jun 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.